title: Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland.
abstract: OBJECTIVE
  To compare projected economic costs and health benefits associated with using pneumococcal conjugate heptavalent vaccine as routine immunisation in healthy children in Switzerland.
  
  
  METHODS
  A cost-utility analysis was performed from both the societal as well as the sickness funds' perspective.
  
  
  METHODS
  Simulated birth cohorts of 80,000 children (the approximate size of a birth cohort in Switzerland) were followed from birth up to age of 5.
  
  
  METHODS
  Reduction in disease burden, costs of vaccination, cost-utility ratio (cost per quality-adjusted life year (QALY)).
  
  
  RESULTS
  With a vaccine coverage of 70% vaccination of newborns only would avert 4 deaths, 8 cases of meningitis, 37 cases of other invasive pneumococcal disease, 150 cases of pneumococcal pneumonia and about 2700 cases of otitis media (OM) per year. The net cost of the vaccination program would be 22 Mio. CHF per year for society and about 19 Mio. CHF for the sickness funds. This results in a cost-utility ratio of 35,700 CHF (approximately 26,300 USD (1)) per QALY from the societal perspective and 39,300 CHF (28,900 USD) per QALY from the sickness funds' perspective. Additional catch-up vaccination of all infants <24 months in the years after vaccine introduction would result in additional benefits at a cost of 33,600 CHF per additional QALY gained. However, if the catch-up vaccination should include all children <60 months, each additional QALY would be gained at a very high cost (162,000 CHF per additional QALY).
  
  
  CONCLUSIONS
  Routine vaccination of healthy infants <2 years in Switzerland can reduce mortality and long term neurologic impairment resulting from invasive pneumococcal disease at a reasonable cost-utility ratio.
authors.affiliation: Hirslanden Research, Seefeldstrasse 214, CH-8008, Zurich, Switzerland.
authors.forename: Silvia M
authors.initials: SM
authors.lastname: Ess
authors.forename: Urs B
authors.initials: UB
authors.lastname: Schaad
authors.forename: Alain
authors.initials: A
authors.lastname: Gervaix
authors.forename: Seline
authors.initials: S
authors.lastname: Pinösch
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Szucs
mesh_terms: D016470:Bacteremia / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D007231:Infant, Newborn; D008586:Meningitis, Pneumococcal / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*; D011018:Pneumonia, Pneumococcal / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D013557:Switzerland / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D022242:Pneumococcal Vaccines